TL;DR
HKIC reported a 14% net portfolio IRR for 2025, alongside HK$6.459 billion of investment income and an HK$1-to-over-HK$8 capital multiplier. The figures are material, but they measure different things and do not establish a public-market benchmark or future return.

Hong Kong has put numbers on its patient-capital model

Hong Kong Investment Corporation’s second annual report is unusually useful because it gives Asian private-market allocators more than a policy narrative. It discloses a 14% net portfolio internal rate of return as at 31 December 2025, HK$6.459 billion of investment income for the year and an operating profit of HK$6.320 billion.

The wholly HKSAR Government-owned investment company also reported total assets of HK$69.705 billion, up 9% from HK$64.007 billion at the end of 2024. Its investment income increased 175% from HK$2.345 billion, while operating profit rose 181% from HK$2.252 billion.

Those figures make the 16 July release intrinsically relevant to Asia’s private-capital market. HKIC manages the Hong Kong Growth Portfolio, Greater Bay Area Investment Fund, Strategic Tech Fund and Co-Investment Fund. Its mandate combines a reasonable medium- to long-term financial return with industrial and economic objectives for Hong Kong.

1. A 14% IRR is not a 14% annual yield

HKIC defines the 14% figure as net IRR after deducting operating costs and expenses incurred by the entities established to invest in underlying portfolio companies. IRR is a cash-flow-sensitive measure: the timing and size of contributions, valuations and distributions affect it. It should not be read as a one-year yield, a promised return or a directly comparable public-equity result.

The report does not provide, alongside the headline IRR, a conventional private-market bridge showing paid-in capital, distributions and residual value by vintage. Without measures such as DPI, TVPI and RVPI, allocators cannot separate cash returned from value that remains in the portfolio or compare the result cleanly with a particular fund cohort.

2. HK$6.459 billion of income includes unrealised gains

The annual report says 2025 investment income comprised interest income and changes in unrealised gains on financial assets measured at fair value through profit or loss. The key financial table does not split the HK$6.459 billion between those two components.

That does not invalidate the result. It defines the next diligence question. A realised cash return and an upward fair-value mark can both contribute to reported performance, but they carry different evidence, liquidity and valuation risks. An allocator needs the valuation policy, realised-versus-unrealised bridge and cash-distribution record before treating accounting income as an exit outcome.

South China Morning Post independently reported the 14% IRR, HK$6.46 billion of investment income, HK$6.3 billion operating profit and HK$69.7 billion of total assets. The Standard separately confirmed the annual-report figures and portfolio expansion. Neither report turns the disclosed IRR into a future-return claim.

3. The greater-than-eight-times multiplier measures mobilisation

HKIC says every HK$1 it invested attracted more than HK$8 of long-term market capital, including money from overseas sovereign wealth funds and pension plans. That is evidence of capital mobilisation around the portfolio. It is not an eight-times return, a distribution multiple or proof that each project has the same co-investment ratio.

The distinction matters for family offices and institutional co-investors. Mobilised capital may widen a company’s financing network and reduce reliance on one balance sheet, but the announcement does not disclose the fee economics, security ranking, governance rights or deployment schedule attached to every outside dollar. Those remain transaction-level questions.

4. Portfolio composition reveals more than the headline return

At the end of 2025, 56% of invested capital was in hard and core technology, 22% in biotechnology and health technology, 9% in new energy and green technology, and 13% in other sectors. By stage, 9% was early-stage, 58% growth-stage and 33% mature. By headquarters, 47% was in mainland China, 28% in Hong Kong and 25% elsewhere.

That mix describes a concentrated strategic-growth portfolio, not a broad proxy for Asia-Pacific private markets. It also helps explain why valuation methods, follow-on funding and exit timing matter. HKIC reported that ten portfolio companies had listed in Hong Kong and that more than 30 had applied or were preparing to apply for listings in 2026. A listing pipeline is relevant exit infrastructure, but an application or listing is not the same as a realised distribution.

As of June 2026, HKIC said it had invested in more than 200 projects. It also plans to extend its reach into next-generation AI, brain-computer interfaces, commercial aerospace, cross-border digital infrastructure and quantum computing, while taking forward an offshore renminbi venture-capital fund. Those additions may change the portfolio’s sector, duration and valuation profile; the 2025 IRR cannot be carried forward to them.

The allocator’s reading

HKIC’s report provides four useful lenses: net IRR, accounting income, capital mobilisation and portfolio composition. They should be read together, not collapsed into one performance claim. For private-market allocators, the next layer of evidence is clear: realised and unrealised attribution, cash distributions, vintage-level results, valuation governance, co-investor rights and the terms under which new strategies will be funded.

Source note: Financial figures, calculation notes and portfolio allocations come from HKIC’s 16 July announcement and its linked 2025 Annual Report. The event and principal figures were independently checked against South China Morning Post and The Standard. This is market analysis, not financial advice. No return, liquidity or allocation forecast is made.

Frequently Asked Questions

What does HKIC’s 14% net IRR measure?

HKIC says the figure is the net internal rate of return on its investment portfolio as at 31 December 2025, calculated after operating costs and expenses incurred by the entities investing in underlying portfolio companies. It is not presented as an annual yield or forecast.

Was HKIC’s HK$6.459 billion of 2025 investment income all realised cash profit?

No such conclusion can be drawn. The annual report says investment income comprised interest income and changes in unrealised gains on financial assets measured at fair value through profit or loss. The key financial table does not split the HK$6.459 billion between those components.

What does HKIC’s HK$1-to-over-HK$8 capital multiplier mean?

HKIC says every HK$1 it invested attracted more than HK$8 of long-term market capital, including capital from sovereign wealth funds and pension plans. This is a capital-mobilisation measure, not an investment return, distribution multiple or liquidity measure.

Where was HKIC’s portfolio allocated at the end of 2025?

By theme, invested capital was 56% hard and core technology, 22% biotechnology and health technology, 9% new energy and green technology and 13% other sectors. By geography, 47% was in mainland China, 28% in Hong Kong and 25% elsewhere.